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Introduction {#sec005}
============

Moyamoya disease (MMD; OMIM 607151) is a rare cerebrovascular condition characterized by a progressive steno-occlusive vasculopathy of the large intracranial arteries with compensatory development of collateral vessels \[[@pone.0179689.ref001]\]. Affected individuals often present with strokes, transient ischemic attacks, and intracerebral hemorrhage \[[@pone.0179689.ref001]\]. The majority of moyamoya patients are of Asian descent. The annual incidence of MMD is estimated to be 0.35--0.94 per 100,000 people in Japan \[[@pone.0179689.ref001],[@pone.0179689.ref002]\], and approximately one-tenth that amount in Europe \[[@pone.0179689.ref003]\]. Epidemiological data have shown a high incidence and prevalence of MMD in Korea. The annual incidence has steadily increased from 1.7 to 2.3 per 100,000 people from 2007 to 2011 \[[@pone.0179689.ref004]\].

A strong association between *RNF213* p.Arg4810Lys (c.14429G\>A, rs112735431) and increased susceptibility for MMD have been reported in previous studies \[[@pone.0179689.ref005],[@pone.0179689.ref006]\]. *RNF213* p.Arg4810Lys is a major genetic risk factor in East Asian MMD patients, demonstrating a predominantly autosomal dominant inheritance pattern with reduced penetrance \[[@pone.0179689.ref006]\]. The frequency of the *RNF213* p.Arg4810Lys variant in East Asian patients was 73--79% \[[@pone.0179689.ref005]--[@pone.0179689.ref007]\]; therefore, other genetic factors contribute to the onset and progression of MMD. In addition to the *RNF213* p.Arg4810Lys variant, other *RNF213* variants have been identified in both East Asian and European patients with MMD \[[@pone.0179689.ref008]--[@pone.0179689.ref010]\]. However, because of the limited numbers of MMD patients used in these studies \[[@pone.0179689.ref005],[@pone.0179689.ref006]\], further study in a large Korean population is necessary. Therefore, we investigated the frequency of MMD-related *RNF213* variants, including *RNF213* p.Arg4810Lys, in a cohort of Korean patients with MMD compared with control populations.

Materials and methods {#sec006}
=====================

Study subjects and *RNF213* variant list {#sec007}
----------------------------------------

We included patients with a diagnosis of MMD at Samsung Medical Center (a tertiary referral hospital in Seoul, Korea) between February 2013 and December 2015. A diagnosis of MMD was based on transfemoral cerebral angiogram findings demonstrating stenosis or occlusion of the terminal portion of the internal carotid artery with the formation of collateral vessels compensating for the arterial occlusion. Based on the Stop Stroke Study Trial of Org 10172 in Acute Stroke Treatment (SSS-TOAST), patients with potential sources of cardioaortic embolism, extracranial atherosclerosis with significant stenosis (≥50%) on the relevant extracranial arteries, other stroke mechanisms (coagulopathy, vasculitis, arterial dissection, etc.), or incomplete evaluations were excluded.

We selected all variants listed in the Human Gene Mutation Database (HGMD professional version of 2015.3) as disease-causing or likely disease-causing *RNF213* variant for MMD. This database provides known gene lesions responsible for human inherited diseases, which are selected on the basis of published studies in the literature \[[@pone.0179689.ref011]\]. A total of 30 *RNF213* variants are summarized in [Table 1](#pone.0179689.t001){ref-type="table"}. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) genotyping was performed for all selected *RNF213* variants. Genomic DNA extracted from peripheral blood leukocytes were subjected to MALDI-TOF MS genotyping. Control data were obtained from the Korean reference genome database for healthy Korean subjects (<http://152.99.75.168/KRGDB/>). The control data consisted of that from 622 and 1,100 Korean individuals. Demographic information including sex and age for the control group were not available due to the Korean Personal Information Protection. In the final step, we compared genotype data between patients and healthy controls. This study was approved by the Institutional Review Board of Samsung Medical Center (IRB approval 2008-02-046-057).

10.1371/journal.pone.0179689.t001

###### Thirty *RNF213* variants associated with moyamoya disease.

![](pone.0179689.t001){#pone.0179689.t001g}

  Location   Nucleotide          Amino acid     HGMD accession   dbSNP
  ---------- ------------------- -------------- ---------------- -------------
  Exon 9     c.1587_1589delCGC   p.Ala531del    CD1410268        NA
  Exon 26    c.4865C\>T          p.Ala1622Val   CM154727         NA
  Exon 41    c.11671A\>G         p.Met3891Val   CM110690         NA
  Exon 42    c.11797G\>A         p.Val3933Met   CM154728         NA
  Exon 43    c.11884A\>G         p.Asn3962Asp   CM116652         rs138615753
  Exon 44    c.11990G\>A         p.Cys3997Tyr   CM1410266        NA
  Exon 44    c.12020C\>G         p.Pro4007Arg   CM129860         NA
  Exon 44    c.12037G\>A         p.Asp4013Asn   CM1111820        rs397514563
  Exon 44    c.12055C\>T         p.Arg4019Cys   CM1410267        rs139265462
  Exon 45    c.12185G\>A         p.Arg4062Gln   CM116653         NA
  Exon 45    c.12226A\>G         p.Ile4076Val   CM1410269        NA
  Exon 46    c.12391C\>T         p.Arg4131Cys   CM154726         NA
  Exon 48    c.12554A\>C         p.Lys4185Thr   CM1414304        NA
  Exon 51    c.13100A\>T         p.Gln4367Leu   CM129861         NA
  Exon 56    c.13699G\>A         p.Val4567Met   CM110691         rs145282452
  Exon 56    c.13756A\>C         p.Thr4586Pro   CM129858         NA
  Exon 57    c.13822C\>T         p.Pro4608Ser   CM116654         NA
  Exon 57    c.13891C\>G         p.Leu4631Val   CM129862         NA
  Exon 59    c.14195A\>C         p.Lys4732Thr   CM1410270        rs148776624
  Exon 59    c.14248G\>A         p.Glu4750Lys   CM155454         NA
  Exon 59    c.14293G\>A         p.Val4765Met   CM110692         NA
  Exon 60    c.14429G\>A         p.Arg4810Lys   CM110689         rs112735431
  Exon 62    c.14587G\>A         p.Asp4863Asn   CM116647         NA
  Exon 63    c.14780G\>A         p.Arg4927Gln   CM155455         NA
  Exon 63    c.14850G\>C         p.Glu4950Asp   CM116648         rs371441113
  Exon 65    c.15062C\>T         p.Ala5021Val   CM116649         rs138130613
  Exon 67    c.15408G\>A         p.Met5136I     CM129859         rs376505157
  Exon 68    c.15480C\>G         p.Asp5160Glu   CM116650         NA
  Exon 68    c.15487G\>A         p.Val5163Ile   CM1410271        rs201733659
  Exon 68    c.15527A\>G         p.Glu5176Gly   CM116651         NA

Abbreviations: dbSNP, single nucleotide polymorphism database; HGMD, Human Gene Mutation Database; NA, not available.

*RNF213* reference accession number: NM_001256071.1

*RNF213* genotyping using MALDI-TOF MS analysis {#sec008}
-----------------------------------------------

Detection of *RNF213* variants was carried out by high-throughput multiplex analysis on a Sequenom MassARRAY MALDI-TOF MS (Sequenom, San Diego, CA, USA). We designed specific primers to flank the mutation sites as well as extension primers to bind adjacent to the mutation sites using MassARRAY assay design software ([S1 Table](#pone.0179689.s001){ref-type="supplementary-material"}). The method involves a multiplex primary polymerase chain reaction (PCR) followed by an iPLEX reaction with a single primer that is specific for each genotype.

A primary PCR was performed by combining 1 μl of genomic DNA (10 ng μl^-1^) with 4 μl of PCR cocktail in a 384-well plate. The PCR cocktail was comprised of 875.5 μl of water, 230.4 μl of PCR buffer, 184.3 μl of 25 m~M~ MgCl~2~, 23.1 μl of dNTP mix (25 m~M~ each dNTP), 460.8 μl of primer mix (500 n~M~ each), and 46.1 μl of PCR enzyme. The plate was then subjected to cycling on a thermal cycler (Model T1 plus; Biometra, Goetingen, Germany), and the cycling conditions were as follows: 1 cycle at 94°C for 4 min, 45 cycles at 94°C for 20 s, 1 cycle at 56°C for 30 s, 1 cycle at 72°C for 1 min, and a final extension step at 72°C for 3 min. Allele discrimination reactions were carried out by adding 2 μl of iPLEX reaction mix to the dephosphorylated primary PCR reaction mix. Reactions were cycled at 94°C for 30 s, followed by 40 cycles at 94°C for 5 s, 1 cycle at 52°C for 5 s, 1 cycle at 80°C for 5 s, and 1 cycle at 72°C for 3 min. The products were spotted onto a 384-spot SpectroCHIP with a MassARRAY Nanodispenser (Sequenom) and analyzed on a MassARRAY Analyzer Compact (Sequenom). If a variant or "no call" was detected in MALDI-TOF MS genotyping, the corresponding exon and intron regions of the genomic DNA were sequenced to confirm the status.

DNA sequencing for *RNF213* variants {#sec009}
------------------------------------

Targeted coding exons and flanking introns of *RNF213* were amplified using primer sets designed by the authors. Genomic DNA was extracted from peripheral blood leukocytes using standard protocols. PCR was performed on a Thermal Cycler 9700 (Applied Biosystems, Foster City, CA, USA). The PCR products were sequenced on an ABI Prism 3730*xl* genetic Analyzer (Applied Biosystems) using the BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems). Obtained sequences were compared with the reference sequence for *RNF213* (NM_001256071.1). All mutations and their putative effects at the protein level were renamed according to the Human Genome Variation Society guidelines.

Statistics {#sec010}
----------

To assess the data quality of *RNF213* variants, *P*-values were calculated by an exact test for Hardy-Weinberg equilibrium. To analyze genotype and allele frequency data, differences between the control and disease groups were compared by a χ^2^ or Fisher's exact test as appropriate. The calculations were performed with VassarStats (<http://vassarstats.net/>), and 95% confidence intervals were calculated for each value. All *P*-values were based on two-sided comparisons, and *P*-values \< 0.05 were considered statistically significant.

Results {#sec011}
=======

Characteristics of the study population {#sec012}
---------------------------------------

Two hundred sixty-four patients with MMD were included in this study: 185 (70.1%) were female, and the average age was 44.4 ± 14.2 years (range: 18--81 years) ([Table 2](#pone.0179689.t002){ref-type="table"}). One hundred sixty-two patients (61.4%) showed bilateral involvement of the internal carotid arteries on transfemoral cerebral angiogram, and 102 (38.6%) patients showed unilateral involvement. Eighty-four (31.8%) patients had ischemic stroke, 55 (20.8%) patients had TIA, 17 (6.4%) patients had hemorrhagic stroke, and 108 (40.9%) patients were asymptomatic ([Table 2](#pone.0179689.t002){ref-type="table"}).

10.1371/journal.pone.0179689.t002

###### Demographic characteristics of 264 Korean patients with MMD.

![](pone.0179689.t002){#pone.0179689.t002g}

  Variable                       No. (%) of patients
  ------------------------------ ---------------------
  Average age in years (range)   44.4 (18--81)
  Sex                            
   Men                           79 (29.9)
   Women                         185 (70.1)
  Laterality                     
   Bilateral                     162 (61.4)
   Unilateral                    102 (38.6)
  Symptoms at onset              
   Ischemic stroke               84 (31.8)
   Transient ischemic attack     55 (20.8)
   Hemorrhage                    17 (6.4)
   Asymptomatic                  108 (40.9)

*RNF213* genotype and allele frequencies in control and patient groups {#sec013}
----------------------------------------------------------------------

Genotype distributions of *RNF213* variants were in Hardy-Weinberg equilibrium. To investigate the associations between *RNF213* variants and MMD, genotype and allele frequencies were analyzed using samples from 264 Korean patients with MMD and two sets of controls comprised of 622 and 1100 individuals, respectively.

The genotype and allele frequencies at the 30 *RNF213* variant loci are listed in [Table 3](#pone.0179689.t003){ref-type="table"}. *RNF213* p.Arg4810Lys was identified in 67.4% (178/264) of patients with MMD. The allele frequency of *RNF213* p.Arg4810Lys was significantly higher in MMD patients than in the 622 controls (33.90% in the MMD group versus 0.80% in the control group; *P*\<0.0001) and in the 1100 controls (33.90% in the MMD group versus 1.05% in the control group; *P*\<0.0001). The odds ratio for an association between the *RNF213* p.Arg4810Lys variant allele and MMD was 63.29 (95% confidence interval, 33.11--120.98) in the 622 controls and 48.55 (95% confidence interval, 31.00--76.03) in the 1100 controls. The p.Ala5021Val (c.15062C\>T, rs138130613) *RNF213* missense variant was identified in 2 patients with MMD (0.8%, 2/264); however, the allele frequency was not significantly different compared to that of the control group (0.38% in the MMD group versus 0.24% in control group; *P* = 1.00). No other *RNF213* variant was identified in patients with MMD.

10.1371/journal.pone.0179689.t003

###### Allele frequencies of 30 *RNF213* variants in Korean patients with moyamoya disease and two population controls.

![](pone.0179689.t003){#pone.0179689.t003g}

                     *RNF213* genotype   Sample size   MMD patients (*N* = 264)   Controls[\*](#t003fn003){ref-type="table-fn"} (*N* = 622)   Controls[\*](#t003fn003){ref-type="table-fn"} (*N* = 1100)   *P*-value[^†^](#t003fn004){ref-type="table-fn"}                                                  
  ------------------ ------------------- ------------- -------------------------- ----------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------- ----------------------- ---------------------- --------------
  p.Ala531del        264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Ala1622Val       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Met3891Val       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Val3933Met       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Asn3962Asp       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Cys3997Tyr       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Pro4007Arg       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Asp4013Asn       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Arg4019Cys       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Arg4062Gln       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Ile4076Val       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Arg4131Cys       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Lys4185Thr       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Gln4367Leu       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Val4567Met       264                 0             0                          264                                                         0                                                            0                                                 0.08 (0.01--0.45)       0                      NA
  p.Thr4586Pro       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Pro4608Ser       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Leu4631Val       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Lys4732Thr       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Glu4750Lys       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Val4765Met       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  **p.Arg4810Lys**   **86**              **177**       **1**                      **264**                                                     **67.42 (61.55--72.79)**                                     **33.90 (29.99--38.04)**                          **0.80 (0.43--1.47)**   **1.05 (0.7--1.57)**   **\<0.0001**
  p.Asp4863Asn       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Arg4927Gln       264                 0             0                          264                                                         0                                                            0                                                 0                                              NA
  p.Glu4950Asp       264                 0             0                          264                                                         0                                                            0                                                 0                       0.09 (0.02--0.33)      NA
  p.Ala5021Val       262                 2             0                          264                                                         0.76 (0.21--2.72)                                            0.38 (0.10--1.37)                                 0.24 (0.08--0.7)        0.14 (0.05--0.41)      1.00
  p.Met5136I         264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Asp5160Glu       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Val5163Ile       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA
  p.Glu5176Gly       264                 0             0                          264                                                         0                                                            0                                                 0                       0                      NA

Abbreviations: CI, confidence interval; Het, heterozygous; Hom, homozygous; MAF, minor allele frequency; NA, not available; WT, wild type.

Significant results are shown in bold.

\*Data from the Korean Reference Genome Database (<http://152.99.75.168/KRGDB/>)

^†^MMD patients vs. controls (*N* = 622 or *N* = 1100)

Discussion {#sec014}
==========

The major finding of this study is that the *RNF213* p.Arg4810Lys variant is the main predisposing allele for MMD in our cohort of 30 previously known mutations. Another rare variant, *RNF213* p.Ala5021Val, was identified, but did not significantly associate with MMD. Our findings are in line with previous research demonstrating that *RNF213* p.Arg4810Lys is the strongest founder variant common in East Asian MMD patients \[[@pone.0179689.ref005],[@pone.0179689.ref006]\].

*RNF213* on chromosome 17q25 has been recognized as the major susceptibility gene for MMD in East Asians \[[@pone.0179689.ref005],[@pone.0179689.ref006]\], and the p.Arg4810Lys variant has been identified in 95% of patients with familial MMD, as well as in 80% of patients with sporadic MMD \[[@pone.0179689.ref005]\]. A recent study conducted in a mouse model deficient in *RNF213* addressed the potential role of *RNF213* alteration in the development of aberrant vascular networks in chronic ischemia \[[@pone.0179689.ref012]\]. However, other functional missense variants of *RNF213* have been identified in both East Asians and European patients with MMD \[[@pone.0179689.ref009],[@pone.0179689.ref010],[@pone.0179689.ref013]\]. Several *RNF213* non-p.Arg4810Lys variants were recently found in Caucasian and East/South Asian cases of MMD \[[@pone.0179689.ref006],[@pone.0179689.ref010],[@pone.0179689.ref014],[@pone.0179689.ref015]\]. Additionally, clinical manifestations and angiographic findings differ between Caucasian and East Asians \[[@pone.0179689.ref016]\]. The *RNF213* p.Arg4810Lys variant is reportedly associated with the ischemic-type MMD, whereas *RNF213* non-p.Arg4810Lys variants are associated with hemorrhagic-type MMD \[[@pone.0179689.ref014]\]. In the present study, 52.6% (139/264) of MMD patients had cerebral ischemia (TIA or cerebral infarction). Only 6.4% (17/264) of the patients had hemorrhage at diagnosis. Although the variant allele was observed at higher frequency in the ischemia group than in the hemorrhage group, this difference was not significant (35.6% and 20.6%, respectively; *P* = 0.08). Further studies of larger cohorts of Asians are required to clarify the association between the *RNF213* p.Arg4810Lys variant and clinical characteristics.

Our study revealed that \~33% of Korean MMD patients in our cohort did not harbor susceptibility variants of *RNF213*, indicating that further studies are required to discover other genetic risk factors for MMD. Several susceptibility genes have been identified for MMD: MMD-2 (gene: *RNF213*) \[[@pone.0179689.ref005],[@pone.0179689.ref006]\], MMD-5 (*ACTA2*) \[[@pone.0179689.ref017]\], and MMD-6 with achalasia (*GUCY1A3*) \[[@pone.0179689.ref018]\]. Loci for the disorder have been mapped to chromosome 3p (MMD-1) \[[@pone.0179689.ref019]\], 8q23 (MMD-3) \[[@pone.0179689.ref020]\], and Xq28 (MMD-4) \[[@pone.0179689.ref021]\]. Further studies on other modifying factors, such as microRNAs and their polymorphisms and biomarkers (e.g., endothelial progenitor cells) are needed \[[@pone.0179689.ref022],[@pone.0179689.ref023]\].

Our study was limited in that we could not determinate whether other *RNF213* rare variants apart from the 30 previously discovered *RNF213* variants were present in patients with MMD. Exome and genome sequencing could be useful tools to identify novel susceptibility genes or variants for MMD. Additionally, our study had a limited sample size. Further studies with larger cohorts including pediatric patients with MMD are needed. Lastly, intracranial stenosis can be caused by atherosclerosis or other causes (e.g., dissection) in adult patients. All patients underwent conventional angiography and high-resolution magnetic resonance imaging to preclude non-MMD pathologies in selected cases, especially when vascular studies showed controversial results in the diagnosis of MMD \[[@pone.0179689.ref024]\].

Conclusions {#sec015}
===========

We confirmed that, in our cohort, *RNF213* p.Arg4810Lys was strongly associated with MMD among the 30 *RNF213* variants listed in the HGMD. Our analysis also indicates that other susceptibility genes exist, providing further insight into the pathogenesis of MMD.
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======================

###### PCR primers used in this study for the MALDI-TOF MS genotyping.
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